TAPSE/sPAP ratio is a marker of cardiorenal syndrome type 2 in the systemic sclerosis EUSTAR cohort. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Arthritis Care & Research = Arthritis Care and Research Année : 2023

TAPSE/sPAP ratio is a marker of cardiorenal syndrome type 2 in the systemic sclerosis EUSTAR cohort.

Amalia Colalillo
  • Fonction : Auteur
Chiara Pellicano
  • Fonction : Auteur
Lidia P. Ananyeva
  • Fonction : Auteur
Giovanna Cuomo
  • Fonction : Auteur
Andrea-Hermina Györfi
  • Fonction : Auteur
László Czirják
  • Fonction : Auteur
Jeska de Vries-Bouwstra
  • Fonction : Auteur
Luc Mouthon
Hadi Poormoghim
  • Fonction : Auteur
Francesco del Galdo
  • Fonction : Auteur
Nicolas Hunzelmann
  • Fonction : Auteur
Julia Spierings
  • Fonction : Auteur
Masataka Kuwana
  • Fonction : Auteur
Edoardo Rosato
  • Fonction : Auteur

Résumé

Objective The aim of the study was to evaluate the association between the tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (sPAP) ratio and estimated glomerular filtration rate (eGFR) and their association with mortality in the European Scleroderma Trials and Research (EUSTAR) cohort. Methods Patients with systemic sclerosis (SSc) from the EUSTAR database with TAPSE, sPAP, and parameters required to calculate eGFR were included. Logistic regression and Cox regression analysis were performed to evaluate TAPSE/sPAP as a risk factor for chronic kidney disease (CKD) and overall survival. Results A total of 2,370 patients with SSc were included; 284 (12%) patients had CKD stage 3a–5. TAPSE/sPAP (odds ratio [OR] 0.479; 95% CI 0.310–0.743; P < 0.001), arterial hypertension (OR 3.118; 95% CI 2.173–4.475; P < 0.001), diastolic dysfunction (OR 1.670; 95% CI 1.148–2.428; P < 0.01), and N-terminal pro-B-type natriuretic peptide (OR 1.165; 95% CI 1.041–1.304; P < 0.01) were associated with CKD stage 3a–5. TAPSE/sPAP ≤0.32 mm/mm Hg (hazard ratio [HR] 3.589; 95% CI 2.236–5.761; P < 0.001), eGFR <60 mL/min per 1.73 m2 (HR 2.818; 95% CI 1.777–4.468; P < 0.001), and age (HR 1.782; 95% CI 1.348–2.356; P < 0.001) were the most significant predictive factors for all-cause mortality. A total of 276 patients with SSc had pulmonary hypertension (PH) confirmed by right heart catheterization, with 69 (25%) having CKD stage 3a–5. No difference was found in eGFR between patients with PH with reduced or normal cardiac index. Conclusion Reduced TAPSE/sPAP ratio is independently associated with CKD. TAPSE/sPAP ratio ≤0.32 mm/mm Hg and eGFR <60 mL/min per 1.73 m2 are prognostic factors for all-cause mortality. In patients with SSc with PH, eGFR is independent by reduced cardiac output.
Fichier principal
Vignette du fichier
Arthritis Care Research - 2023 - Colalillo - Tricuspid Annular Plane Systolic Excursion Systolic Pulmonary Artery.pdf (427.07 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04513208 , version 1 (20-03-2024)

Licence

Identifiants

Citer

Amalia Colalillo, Chiara Pellicano, Lidia P. Ananyeva, Eric Hachulla, Giovanna Cuomo, et al.. TAPSE/sPAP ratio is a marker of cardiorenal syndrome type 2 in the systemic sclerosis EUSTAR cohort.. Arthritis Care & Research = Arthritis Care and Research, 2023, Arthritis Care & Research = Arthritis Care and Research, ⟨10.1002/acr.25196⟩. ⟨hal-04513208⟩

Collections

RIIP UNIV-LILLE
2 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More